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Cltaprer 10 
General Discussiiam and Main Comcllulsiaionrs 
Tim sl~apler 8s partly based on b o k  contrrbuuonm: 
JC iiagcr, MI Posua~a. K Tolley, 1 Kern~elly: hsie~#menl of the Soclo-ec~nrmic lmyhaci of  klDSj Pmm 
osthoal tswinrds m&tinatleml xenarrbs. Inbn' D Rmmons, W Hardy, K Tolley (13s )  Tlre Beonr~ln~c arvd 
Socrad lmpact of AlDS tn Europe. London Ca.wll 1995, pp 40-53. 
Ml Posmn. H Kornarou. W Paparrms. R k l d l ,  K "Folley, J Kyr~opoulos, JG Jager for the Europadn Resarclr 
Tern on AdDS Soemnos: HospiYd Care for Persons wtth AIDS im Greece sort Ule Netbetlands; ilssmmcnfl 
of rwnenrt aod hiwe impact. In I Kynopoolue (Ed) AIDS Cost A S I R ~ ~ S I S  and Parlent Cle8s1ficatfon (tn press). 

Genpml Diiscmsion c3;an' Main Coszhro~s  
Ths bhesls addresses the economic Impact of HIVSAIDS In the Netherla~vdls and the 
European Union (EU) as a aide. It provides descruptions of rnetlrods to link epldemiolo- 
g d  modelling to economic information for soenalo analysis on AhDS i~azpacrs. T11e 
chapters refer ra dufferent methodological and empirial estirnatia~l issues. First, metLhds 
to estimate parameter values for rnadels of AIDS economic Impact are t r e a d  (chapters 3 
and 43 a indlrcated in one of Cl~e objectives of thas thesis. Second, ~netYrdologilcal aspects 
of Imkmg population-dynam~ml and statistical epidemiolog~cal models and econotnic 
informarion are dealt with i n  chapters 4,s and 7, with expl~cit consideratlovi grven to 
r@OUhCie util~zmt~on and costs i ~ a  different stages OF the disease. Also, chapter 7 addresses 
quality criteria for econornlc impact suudles attributing to the development of the Standm- 
dlsecl Cosxlng Framework Pbr HlViAlDS hospital care. FOP planning purposes, potential 
future trends in the epidemic have k 1 1  translated into healtlr-care resource needs and 
corresponding cosfs at the e rational (chapters 5 and 9) aivd EU-leveh (cliapters 4, 8 arrd 93 
Cliapser 6 deals w ~ h  a requested application of the AIDS-impact rndel for policy- 
mak~np, estiaqjatrng rhe lrnpar-t of AIDS on life lnsuranr-e. The comparability of AlDS 
Impacts an hosp~~al resource utulimtion in different countrues and with ather diseases is 
treated 111 chapter 9 and the Annex of this thesls. Some issues surpassing the level of an 
andnvidual chapter are stressed hrr the current concluding chapter. These issues relate For 
example ltlo checking resource-need projections for years. chat have yet gone by, broade- 
lvlng the hospital costing viewpoint to other health-care secmrs, policy implications of the 
scenario work (at Ll~e national and EU-levels) and rnel8.codological aspats of llnkinig 
lep~derniological !nodeis and economic information (incidence-based versus prevalence- 
based Impact calculus). Thus final chapter concludes wS~lu evaluating a10 the objectives in 
the same order as presented in chapter 1. 
10.2 Dkcefese-staging and ~asb-star&rdiz~ti0111 cplf HEWJAIDS 
Prevllously, doubts have been expressed about the quality of published estimates of llrc 
costs of HEVIAIDS hosprkl treatment and care grduced far EU-caurrtrres [66,218]. The 
explicut use of a standardisad framework for cast estimation would help improve the 
quality of methods in studies on resource, utilimtion and casts and enhance the comparabi- 
lily 06 cost estimates produced. Thiie, maximises their wsefukness for a range of research 
and policy purposes at the local, national and muitl-~at~onal levels. W~thtru the Standsdlr- 
sed  Hosp~hl Costing Framework (SHCE) features of gCpMdl qualulty ~tudies are defined and 
these have Ereen applied to EW-studies on hospital m h .  Fearures cyf good quality refer to 
rep~%n"taveness, the possibitlity lclf disaggregatuon, producing homogeneous oost groups 
and adherence to elementary slandards of cost-ofi~llnws tudles. The SHCF 1s not 
~nknded to be a pre~riptlve Instrument. I t  is used rretrogpectively for reviewing exlstlng 
mst stilld~es and mu be prospectively used for helping in the development and mndurtion 
of new cost studies. The frmework represents a combination of g a d  costlng practice and 
technical shndards for cost esturnal~on. AN Important area wtth uncerlillnv about the besi 
method tcy icmploy is. the chorce of h e  patient classificat~on system for HlViPlIDS swges 
(for example. CDC-stages, CD4-cell counts. viral load, AIDS-defirr~ng diagnzoses or 
stages derlwed from varratlon in heal th-care resource ut~limtion) [346]. Whatever 
classif~cat~on is used, if It is to be useful for prospective fimncang and projection of 
health care 11 should reflect severity of ~llrress, as th~s has been found to be the major 
indicator of waslation In healllli-care resource utilization (34'71. 
Prufiles on hosp~tal Inpatient days utillzaltiun dur~ng the AIDS-skge show that a 
arrajor part of health-care resources are ut~lized in the terminal phase. Thus IS an imporant 
flazdlng wit11 respwt lo tire prevtotis section in that hospital resource utilizat~on and cost 
studues ought to be ~trrndardlzed accocdrng to the patient distribution over terminal and 
nun-term~nal phases. The enlpir~cal approach chosen dtfferentiates two substager: the fkral 
half year of AlDS preceding death (late stage) and rtie foregoing perrcad (chronic stage). 
As illustrated in this thesis, hospital rnpatlent days utilizat~on and hospital costs In the late: 
stage are several tsones ~Eiose in the chromic stage. Next to the need for standardizung the 
palient population, chapter 7 convlnclngly shows the iinportance of disease-staging for 
f~rovudung val~d future projections utrder a range of wsumptrons. In partuculas tn LEre 
silualion of HIQSAIDS with rapid medical developments and reJated lrnprowements in  
survival, neglectuon of diseasc-slagitig is sllrown ro overproject hospital bed needs and 
costs by almost 15% over a period of f~ve  years into tlie future. Of course, turther 
lrnprovemenls in projcclfon might be attained by di~t~nguishing more than two substages 
Oibv~ously, tl~rs staging concept ts also relevant for other dl~seases. As slud~es from 
r32e 145 showed, ppy health-care costs and l~ospitzrl discharges urr the lasl year of life 
amount to approx6mately seweia xinles those in other stages of duease. Gathering compara- 
ble informatfan and develop~ilg sitnllar rnetl~dology on diseases such as respiratory 
disease, card iovaxular disease and cancer, is needed and could beu~efit policy decisiorrs In 
ll~ese fields. For example, Kiwop~naolrscl~ap et ol. illustrated tile importance of choosing an 
qpropriare diswe-skging for constructing fumre smtlazias on Dutch cancer wsts 13481, 
They i n t~d~d~ce  thr e stages: an incidence phase, an intermediate phase and a lasf yea r .  
Their analysis shows that - under specific assurnptlons - a prevalence-based n~ruciiell 
neglecting disease-stages mght overproject cancer costs in 21005 by up to 20%. Although 
he disease-stag~ngs for cancer and HlYlAIDS are still rather crude tn only account~vlg for 
the major dynamics in disease progression, the type of conclusiolns reached are rather 
slrntlar: neglecting d~swe-staging might signifiaraitly misproject health-care resources and 
costs. in Future scenarios. Sraginrg of disease for economic reasons can follow different 
strategies, depending on purpose, d~sease characteristic and dau availability; they 
ty[~iullly have to be developed, motivated and tested just as any other analytical concept 
in eco110m~c ewaluat~on and costing. 
10.3 Linking Epidemiolioigy and Ecaoomics 
Results oh epidemiological models and economic information can be linked prewalence- 
based or incidence-based to assess and project health-care resources and cask  Twdition- 
slay, healtin. economic research uses two basic methods far expressing the econo~nic 
impact of disease, labelled incidence-based and prevalence-based metlads 1401. The first 
concerns accoun~ing lifetime health-care resources to the year of' incidence of disease (see 
chapters T and 9). The second method concerns an annualizatioaa of these lifetime healebl- 
care resources (see for example, chapters 5 and 8). To cover che hll ~einomic impact of 
a health-care ~ritervention, it is necessary to amalyse the lifetime consequences for 
resource needs ~ncurred by a representative case. This incidence-based spproaclr does 
however assume that the future health-care kcbinaologies will aeirrain the same as in khe 
analysis, and also extends all other assurnptlons up to the time until the last incident case 
has  been dealt with. If the assumption of everything staying equal holds true for the 
p c r i d  of analysts, and if the full economic impact 8s whiat is be~ng referred to i n  a 
decision context (for example, in decisions on prevenrlon ~nvcstaneaatslbudgers), the 
~ncudence-bas4 approach IS the more appropriate one. I f  on tile other hand, the budget 
Ionpace of a health-care technology is the fwus of analysis, arid if this impact is expect& 
to change wrulh new treatment technologies, the11 dle prevalence-based approach, applied 
over a well-defined period of analysis, wil l  be more appropriate bo support decisiorts on 
the mnomic side. With respect bo the full economic impact both methods are myoplc. 
On the short-term however, the incidence and prevalena-based approaches may differ 
even when applied to the game epldemiologio: d z  set. As an example, the r e n t  
inrrcrduclion of Highly Actrve Anrnrerrov~ral Therapy (MAARV ~n HIV [raiment m y  
serve. On trine short-term HAART % e m s  to cause myor improvements nn health and 
related cuts in hospitalizations. As a cjomquence, prevalence-bas4 assessment for 
budgetting purposes one or two years ahead ~ndimes reduct~ons un hospital budgets for 
HIVIAIDS care 1349j. tlowever, resource-in&~~srve and costly law stages of HSVJklDS 
arc merely shif&d a few years ahead and on a Iifethme basis msls will rise, also because 
HAART is qulte expensive. An unciclence-bawd approach would typically show the hi*er 
development, whereas a prevalence-baed approach might fwus on the shorf-lerni cast 
rductiow only. In consequence, i~nplicatioils drawn for health polucy might differ 
depending an the approach and presentation used. Obviously, the framework for linking 
epidem~ology and economics sholuld encompass the passibiliry of uslazg both types of 
assessmenu and projectlolu. The developed framework in this chesus sarisfhes this 
co~adition. Final1 y and completing tihe developed framework, canfidence intcmals and 
sensitivity analyses have been el;lborated for various aspects (for example, per person- 
year monetary costs of AlDS and the duration of stay in che AEDS-stage). 
11101.41 Dutch Scenario Rmiillts 
A1 the tlma we performed the Durcbl AIDS sioenarno study (chapter 4) reliable natlonal 
dak on hosp~tal resource utilization for the new disease HIWfAIDS were lacking [3501. 
Dur~ng the 19% the coding of H1VIAIDS hospttal care has become integrated in ttve 
routirne daily lrospftal adlninistration [351]1. Over 99% of Dutch Erosp~tals contribute to ehe 
nalioi-tal hospital register of SlG Health Care Lnforrnathon (Utrecht). In 1993, hospital 
~nparient days for HIWJAIIDS as primary diagnosis amounted to 20 600 for AlDS and 
2300 for the pre-AIDS stages (codes 1042 for AIDS, 043 for AIDS Related Complex and 
0144 for other NIV). Tlre estimate for hospital inpatient days in 1993 amounts lo 39 
ror AIDS and 5400 for the pro-AIDS stages (chapter 5) .  Using more recent information 
rliac possibly better reflects hospital practlce in the L990s, the figure for AlDS was 
updated to 30 100 iii chapter 9. An ~rnporlrant drawback lor comparing the estimation and 
tl~c rcgistrat~on involves the classuftcat~on systems used, that do not enltirely match. The 
esrirnatcs are based lair tb~e AIDS surveillance case defirnltion, whereas the national 
repastration applies the 9th sevlsion of the lnternatuonal Classifisatnon of Diseases. 
Bemuse the AlDS surveillance case defitritiart lncludes slightly more disease complicati- 

iarfmd persons who survive longer than 2 years rru the AIDS sfage. Liferime pre-AEDS 
ho$pital msls can be derived srraightfoward from chapter 5 t~ amount 23 lW ECUs. 
an iovervjew on the economic impact of AIDS in Europe, J a e r  er d. 1107) prov~dd  a~ 
extensfon of the Dutch smnartos on hosp~tal irmpacrs to other $=tars of healch care. For 
patien& in the pre-AIDS s w e s  they estrmaeed costs per person-year (ppy) of LZCJ EClh 
far the GP and 4 120 ECUs for earby AZT-trwrmenr (50U mg/dayj, during respectively? 
a~ld 1 yeass in average. For PWAs these ppy costs amount to 2810 ECUs for the GP, fit35 
ECUs for home care (district nurse), 1615 ECUs for home help and 375 ECWs for the 
nursing home. Elaborating on [lie expected lifetime Xlospifal costs, tom1 llifetime health- 
case cos& would be 75 TOO ECUs. So, on total lifetime health-care costs the share of 
non-haspi~l costs is estimalled to be relatrvely small with only 12%. In future projections 
of  be total health-care casts II w a  however showti that the share of home care grows in 
all scenarios i~~vestagated. This 1s a consequence of ep~demrololgical dewelopments solely, 
and the Dutch government policy of substrtuting home care for hospital care miglrt be 
expected to sharpen this; trend. In order to adequately monitor developments in rile cos& 
of ESPYIAIDS 11 1s neclesary lo set up a patient-based monitoring system nn l~olne care that 
is anlalogous to the one already exist~ng in the hospital sec t r .  
10.5 Elatemion of EU-results on Hospital Care 
Isor  he EU-level  his thesis focusses on the impact of die AIDS-stage on the hospilal 
resource needs (chapter 8) and Ihosp~tal costs (chapter 4). Tolley d nl. 12761 provide solsre 
details from a revlew of EU cost studies publislred between 1985-1995. It was possible to 
make comparisons of inpatient and oarlpatierrt costs and to a limited extent of day-care 
costs, by AlDS and preAlDS stages for a number of EU-countries [95,353,354]. This 
review enables the update of d ~ e  EW cost figures i r ~  chapter 4 to reflect the 1999 monebry 
cost projectnon. For tlris purpose, costs have been traa~sformed from or~ginal prlce year 
and Iwal currency to 1993 ECUs, using country-specific Realth-care cxpend~ture price 
~ndrces and the latest availalrle healtll-are-specific purchasing power parities 13.551. 
Resulting Irospital costs ppy in the period 1988-1992 are be~weesa 20-40 rhousand ECVs 
for AIDS patients across a range of EU-countries. In colabination with the varlous 
scenarios this range: indicates total haspikt costs in LW9 to vary between 1.1 and 3.4 
billion ECUs, co~npared to the baseline Ievel around 0.8 - 1 .G billion ECUs in 1993. I f  
the upper lranit were the actual figure, 19919 hosp~tal costs would reflect over 1 % of the 
current health-care expenditure of all ELI-countries. One should rmlize though that these 
future projections don" include any trends in ppy haspita1 costs. 
Whereas utilization has  declined over time in the late eighties and early lnin~eties in 
all studies and mwntries for which txend data are availabie, any changes in hospiml cosm 
gpy: have been far less dramatic [62,65,153,285,286-28811 Possible explrslnatiolrs are that 
he ihatewily of care and unit wsB of resources have increased and more expensive 
nzedicauons have been introduced. For example, the recent in~eaduction of antiretrovural 
combination trnple therapy involves relatively high costs of approxitnateJy 
15 01[DO ECUs per year 135161. However, as a consequence of the rrew therapy, cuts un 
HIVIAIDS hospitalizations have been reported in h s  Arrgeles, New York and France 
1357-3591. Another study shows that benefits of averted haspiral care might even surpass 
the ~neremenml costs asswiated to the new therapy 13603. The calculatmns in cl~apter 8 
an hospital bed needs for the EW after widespread ~ntrductioi~, of triple cambunation 
rht7rap-j indeed show that significant reductions iaa prevalence-based mlculated bed needs 
might result. As mentioned, it can be assumed that the costly (late) AIDS-stage is n~erely 
postponed arrd not prevented, andl lifetime hospital bed needs and casts per HTQ-infected 
person Increase. 
Tolley er at. 12768 indicate that hospital costs are between 2 thousand (asymptoma- 
I I C  HlV in LEle U K  in the period 1987-1989) and 10 thousand (symptomatic HlV an Spain 
In 1990) EGWs ppy for pre-AlDS stage patients, corresponding to 5 % and 40% of the 
corresponding AIDS flgures. In particular, levels of ppy ralpatlent days are significantly 
lower for !he pre-AbDS stages, whereas the outpatient hospital ut~lunticm levels for AIDS 
andl pre-AIDS stages are quite similar. For example, in one Prealch study oulparienc visits 
equal in both stages at approximately seven ppy 1281). Jager d 81. [I071 extended the 
prc l~m ~ n x y  scenario results of cl.lapter 4 'to encompass some of the ind irect costs as well. 
I n  particular, they focus ON the potential years of life lost QPYLL) due AIDS deaths. 
PYLL provide a proxy of i~rdlrect costs of MlVJAIDS In Llle EU, as a monetary value of 
the years lost 12% riot been estimated. Using an  annual incidea~m-based procedure, 
they arumaced the number of PYLI, art the end of the century no range berweetr 203 8WO 
and 520 500. As illustrated by a number of studies (P44.361,362( and for some selected 
ED-counales. P911,L for AEDS has surpassed those due Lo oillei- infectious d~seases and is 
in the order of nnagnitvde of those due to suicide and r o d  accdents. Recently, a possible 
doubling of PYLE, up lo the year 2 W  in the Netherlands compared to the 1990-level has 
ken  rndicratledl by lager et al. [ 1111. Is us shown that PYI-I, due to AaDS approaches cllose 
of dhabetes, several types a[ cancer and cllronic respiratory disease. 
10.6 Impact of Gmnaric Andysh on MeaYblcane Policies 
'The scenario analysis far HPVIAIDS In the Netherlands influenced the development of 
health-care pali~cies at the naeianaf and the international level. At the mriomil level, the 
summary and rmmrnendations of the Soemno Study [ lOl ]  were pmsd through to [he 
delegates of the Dutch Lower House to serve in the discussions on AIDS-grolicles ~ n ,  1992 
[363]. A specific request referred to an advise on the global cost-effectiveness of the 
national budget of 944 OlUO ECUs for campaigns and pro~ects to prevent the further spread 
of HlV w ~ t h ~ n  Lhe Dutch papulacion [3@1. Qisclounting the lifetume hospital msts per 
E(1 W-infected person at 5 % per year for 14 years between infection and death, it may be 
argued, from an economic point of view, that such budget would start to be cost-effective 
if niore than approximately 201 new infections would be prevented on an annual basis. 
Thrs seems quite feasible. Moreover, if the mdlrlect costs a f  WIV infection were taken 
into account, one could qualify the budget as cost-effecrive wlth even fewer new anfwri- 
crns prevented required. Thus there was an economic xgument in favour of the presenlt 
prevelvtlon budget unless of course the budget could be spent on another disease prevent!- 
on area that has a better cost-effectiveness ratlo. 
i n  cl-rapter 6 el~e request for a study or) the impact of AIDS on life imwrance was 
discussed. Also, souire economic analyses in H1W prewention and treatment drew on work 
performed In the Scenasro Study. For example, cost-effectiveness of HIV combination- 
rherapy after percutaneous exposures of Dutcli medical perso~lell was calculated al 
PLO 300 - 88 600 net direct costs per life-year gained [365].  The study suggests a shape- 
ning of indication to improve cost-effective~~ess. Furthermore, in 1990 a sludy on the 
elialuat~can of HlV screening atarong pregnatrt women in Amsberdam was started. One o i  
the goals of the study was t investigate the cost-benefit ratio 13661. Benefits were 
though. to occur through possibly preventing rtze birth of an HIV-~nfwted child and 
associated health-care costs, if an H1Y-infected pregnant woman decides to terminate 
prcgnailcy. Casling T~gures detlved from the Scenario Study were used. At present, an 
evalualtlchn study of' 6-flV-acreenung is much more complex since several new factors Bravc 
proven tu arfecl both the vertical txansrn~ssion probability and the casts, such as 
AZT/Zidovudine veattncnt during and after pregnancy, breast-feeding versus formula 
feeding and an elective ceasasian sectlon. Furthermore, early detection of HIIS-infecraon 
tElrouglr screening and early uptake of anairetrovrral treatment might also have beneficla1 
efFecw on llre progression of HIV i n  the mother. To cower these recent developrnerlts and 
insights a model lras bean developed and a first application to England has been elabora- 
td [U67-3703. 
From itre start of the Dutch Scenmo Study, it was &e objective to build a 
~cmaria ma! ytlc approach that could easily bHe extended to foreign s~tuatio~as 1 lm]. 
Thereiore, the methodoiogy of the approach and the illustrative results for the NePher- 
lands have oficn been highlighted at inarnat~oml conferences. Furthermore, the Dutch 
Swmuio Team was ~nvoived irr meetings of several working groups a f  the ELI and the 
World Health Organzzatlon on the economic inlpact of AIDS 2 109,130,303,309,371 1. 
Natloml study groups from Greece, Spain and France were zrdvtsed on scenarro conslruc- 
tlon for their respecrlve countries 1274,372-3743. In addrit~on, future projects on tlre costs 
of A1DS in France and Belgium were drawn up with explicif reference to our scenario 
mefhmlology [374,375]. During 1993 the finalized Dutch Seemarlo Stludy and rel~ted 
publ~catlons were crucial for being ass~grreid with tlve grant for multi-nathnl AIDS 
scenarios [ELI-grant PL941723 of DG XII). A preliminary verslan of chapter 8 of flits 
lhesis was ~lntegrated urr the final report of another EU-project in DG V 1951. As ullusrm- 
ced in Chapter 9 of this thesis, the standardized sceliraria analytic approach enables 
rnrernatronal comparisons. So in consequence, a rnonltoring system of AIDS impacts itz 
Europe has been developed that addresses the wide range of epidemiology. economic 
aspects and societal responses. The ilnportance of such a system was stressed by clre 
Council of  Europe in 1992, un order to enable a proper timing of rapid reactrorl prmedu- 
res lo new eanerglng develeprnents in the HlVlAIDS epidemic, treatmerib a~ id  care [37(4]. 
More recently, a similar argument was published Vaccine 13773. Finally, during the 
~nrerinalional AIDS Conference in Vancouver the need for stauldaadized procedures on 
performing ecernamlc impacl assessments to help health-care policy develchplnent uwa 
stressed h2781. 
The studies on A[DS scenario analysis in this thesis, provide an example of 
sceliarlo analys~s in infectlous diseases. AS infectious diseases exhibrt their clrarac.ter~stic 
dynaml~s,  extension of the "traditional'" cast-of-illness approach is motivaked in his thesis. 
rills e x t e n d d  aapproaclv is labelled dynamic cost-of-illness assessment. Combunlng this 
approach w ~ t h  scenario analysis - where a set of different assunlprloris on core-parameters 
1s investigated - prov~des !he basis for cosr-effectiveness analysis in infeclious d~searje 
preventson and treatment 13791. Above, examples on cost-effwtrveness analysis of HIV- 
screening rn pregnant wonlen and post-exposure HlW proplzylaxus were mentioned. 
Examples of the exrension of tlre approach to otlher infectious dlseaes refer to scraeninp 
for C h h y d i n  arachomfix [380-3821 and Influenza vaccination 1383-3851. Scenario 
analysis has already beerm mentioned as an integral part of oose-effmtivenms 1311, and this 
seems do be true rn particular for infetlous diseases. Other specific features of cost; 
effectiveness analysis in infe%t~ous d i~as t zq  lallustratd in this thesis refer to rhe linkage 
with a m&el for the spread of the disease and the ~mportance of solnnd casting figures on 
11fetlme: and per p r s o n - y a r  basts. Ultimately, this rhesls s e e b  to ateibute to the 
development olf guidelines for cast-effectiveness in infectious diseases [586,3871. 
Guidelines should be applned for the estimation of IdIVIAIDS-related personal h e a l h m e  
cost%, allowing valmd comparisons between studies performed at different times and 
settings by d1fferea.s~ researchers. (objective 1,  chaphers 3 and 7) 
In  general, there is a need for a standardized approach to cost-of-illness studies to 
increase rhe comparability of studiw. (objective 2; chapters 4 anel 7) 
Tlie clioice of an appropriate disewe-staging averts structural biases in projections of 
hospital care and costs. (objective 3; cluapters 5 "7 and 8) 
Estilliaters of the resources and costs of hiospltal care for HLW!AIDS can be used for 
pla~lning at the national or multi-nax~onal level if a shndardized/generic approach rn 
epidem~ological modelling, data-gathering and severity-stagung is applied. (objective 4; 
chapters 3 aa-ud 4) 
In the Netherlands, ppy hosp~tal costs in the late stage of CDC IV are almost threefold 
those in the chroaaic CDC-IV stage. Lifetime costs from the time of HIV-infection 
onwards are est~mated bo amount 76 C#DO ECUs, hospital costs constitute almost 90% of 
this figure. (objective 5 ;  chapters 5 and 95 
Studies rru several EU-countries show that utilization of hospital lnpatier~t days In the a r e -  
~lntensive late stage of AEDS is twice to tenfold that rn tlre chronic stage. In mosr 
~nvestbgated cowavtries total hospital contacts in the chronic stage we approximaltely half of 
those In the tale stage, (objective 5; clrapter 8) 
Dutch scenarios ddernonstrare tllrat approxirnatelly cane quarter to a half percent of total 
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hospital msts will be required for HlVJAlDS by the end off the century, a slseabLe bur 
pr&ebly managable proportion. Cost prajwtiom in several scenarios ~ndicate a range for 
AlDS Zlolspntal costs of 0.5 and 1.0% of t aa l  EU-expenditures on hospital care by the end 
of t he  century. (objective 6; chapters 3, 5 and 10). 
Hospital bed nleeds for AIDS in the EU will amount to 0.5% to 0.65% of all hospital 
M s  available in the EU. Sensitivity analysis s h m s  d~at new w~nblnation triple therapy 
might lower the estimate Tor hospital beds 'by 20-30%. (objective 6: chapter 8) 
Statistical mnfidence limits in combination with several scenarios 0x1 hospital bed needs 
for AIDS by the end of the century, hndlicate a range of 0.2 % Pi60 0.3 % of curre~rtly 
available hosptfal beds in the Netherlands. (objective 6; chapters 5 and 9) 
Projected lrospital bed needs in the Netherlands for HI'IS/A1DS by tlre end of the celailury 
are lim~ted cornpared to pro~~eclions for coronary Ileast disease. stroke and d~abetes. 
(ohjectnve 7; chapter 5 a r~d  annex) 
Quantitative inforrnatlorr on hospital m e  for AIDS indicates that it is organised different- 
ly Inr the various EO-countries, varytng from high inpatient (France) or outpatient 
(Greece) znvulvements to a mlxed organisatton form (Netherlands). (objective 7; chapter 
81 
Dufferences in AlDS care between two selected countries can be cxplai~~ed from differen- 
ces in the respective health-care systems. (objective 8; chapter 9) 
Scenario analysis on economlc impacts of HlWiiAllDS has influenced the devellaprnene of 
health-cxc policies at rhe national - advise on life-insura~am Impact, plailraing and 
C ~ Q I I ~ ) ~ T I I C  e v a l l ~ a t i o ~ ~  - and rn~rrrat~onal level - advrsory roJe in set-up of foreiIgn AIDS 
scerurso sludres. (objwt~ve 9; chapter 6,9 and 10) 
The dynamic cost-of-illness approach for I-IIW/AlDS can be applled to other ilrfecrious 
d!seaxzs and therefatre merely serves as an illusballon for analyses in, for example 
Influema and Chlamydia tmchamru. (objeaive 10; chapter YO) 
scenario analytic approach mlr be rntegrated in HiYJAlDS cost-efffectiveness analysis 
(objstive 1 1; chapter 10) 
3n this thesis a dynamic cost-of-f-lllness approach has hwn developed for HIV/AIDS. The 
appraach esteems the importance of l~nking cast-of-~Elness with epidemiological mcdelhng 
Into future menmios. Further, the relevance of drswe staging in costing and smnxio 
analysis has ban  demonstrated and des~erves broad atkntion in  rhe shndardimt~on of 
costing methods. Future r e ~ a c h  shoullrd be directed &I the development of dynamic cost- 
effectiveness analysis OF treatment and preverltjon for infectnous dismw. This type of 
regearcl? is currently In progress in both nationaP and internatuoml unitiatlves 1488,3891 
